AMZNprintsminutestrendsdividendsdrawdownsP/E 28.4macronarrativesvolatilitybuybackssentiment+0.8%marginsMSFTPMI 52.1momentumdividendsflowsPMI 52.1digeststhreadsvolatilityearnings callsvolumesβ 1.24breakoutsnewsflow2s10sliquidityheadlines−1.2%breakoutsnoiseGOOGLbuybacksrevisionstrendsPMI 52.1briefstickersnoiseGDPsentimentchattertranscriptsGOOGLsentimentvolatilitybuybacksMSFTwhispersMETAsessionsyield curves13FfuturesdowngradesPMI 52.1headlinesthe tapeflowsdowngradesfutures+0.8%earnings callstranscriptsclosesgammacatalystsrevisionsvolatilitysentimentchatter+2.41%earnings callssentimentfilingstrends10y 4.21%cyclesbuybackswiresspx 0dtewhisperstickersQ3trendsnewsflowearnings callsWTI 78.2sentimentnoisethreadsrumorsnarrativesFOMCconsensusestimatesmomentumYoY +18%tickersmomentumprintsβ 1.24revisions

momentumheadlines52w hipositioning2s10sfilingstrendsprintstrendsmacrocyclesnoise2s10smacroQ3narrativesheadlinesflowscyclesnarrativesspreadstranscriptsdowngradesupgradeswhisperswhispersminutesthe tapeNDXfuturesminutesyield curves52w hithe tapeFOMCcatalystsbriefsthe tapeNVDAguidancetrends52w hidrawdowns2s10swhispersmomentumdrawdownsbuybacks

PCEliquiditysentimentbreakoutsdowngradesP/E 28.4threadsAAPLSPXvolatilityNDXflowscyclesliquidityestimatesEPS 4.12

ZLAB · NASDAQ · Biotechnology

Zai Lab (ADR) (ZLAB)

Develops and commercializes therapies through partnerships and internal research.

$26.69

vs last close+0.26 (+0.98%)

In millions of USD, except per-share figures

In millions	Q3 FY23Sep 2023	Q4 FY23Dec 2023	Q1 FY24Mar 2024	Q2 FY24Jun 2024	Q3 FY24Sep 2024	Q4 FY24Dec 2024	Q1 FY25Mar 2025	Q2 FY25Jun 2025	Q3 FY25Sep 2025	Q4 FY25Dec 2025	Q1 FY26Mar 2026	Q2 FY26Jun 2026
Revenue	69	66	87	101	102	109	106	110	116	128	100	106
Cost of revenue	25	25	34	35	37	42	39	43	47	62	38	48
Gross profit	44	41	54	65	65	67	68	67	69	65	61	58
	127	165	124	141	133	135	124	122	118	135	131	135
Research & development	59	82	55	62	66	52	61	51	48	62	66	62
	69	83	69	80	67	83	63	71	70	73	65	73
Selling & marketing	0	0	0	0	0	0	0	28	29	0	0	0
General & administrative	69	83	69	80	67	83	63	43	41	73	65	73
Other expenses	0	0	0	0	0	0	0	0	0	0	0	0
Operating income	−84	−124	−70	−76	−68	−68	−56	−55	−49	−69	−69	−76
	14	29	17	−4	26	−14	8	14	13	16	20	25
Interest income	9	10	10	9	9	9	9	9	8	7	6	6
Interest expense	0	0	0	0	1	1	1	1	1	1	2	2
Other non-operating income	0	−2	−17	4	−27	13	−9	−15	−14	−17	−21	−26
Income before tax	−69	−95	−53	−80	−42	−82	−48	−41	−36	−53	−50	−52
Income tax expense	0	0	0	0	0	0	0	0	0	−3	1	−1
Net income from continuing operations	−69	−95	−53	−80	−42	−82	−48	−41	−36	−50	−51	−51
Net income	−69	−95	−53	−80	−42	−82	−48	−41	−36	−50	−51	−51
EPS, basic	−$7.10	−$9.80	−$5.50	−$8.20	−$4.30	−$0.80	−$0.45	−$0.37	−$0.33	−$0.46	−$0.50	−$0.50
EPS, diluted	−$7.10	−$9.80	−$5.50	−$8.20	−$4.30	−$0.80	−$0.45	−$0.37	−$0.33	−$0.46	−$0.50	−$0.50
Weighted average shares, basic	10	10	10	10	10	102	108	109	110	111	111	112
Weighted average shares, diluted	10	10	10	10	10	102	108	109	110	111	111	112
EBITDA	−82	−119	−50	−77	−38	−75	−44	−36	−31	−48	−44	−46
Depreciation & amortization	2	2	3	3	3	5	3	4	4	4	4	4
EBIT	−84	−122	−53	−80	−41	−81	−47	−39	−35	−52	−48	−50